Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 195,700 shares, a growth of 301.8% from the October 15th total of 48,700 shares. Based on an average daily trading volume, of 1,660,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.4% of the company’s stock are short sold.

Windtree Therapeutics Trading Down 6.2 %

NASDAQ WINT opened at $0.56 on Wednesday. Windtree Therapeutics has a 12 month low of $0.53 and a 12 month high of $22.36. The firm has a market capitalization of $332,111.00, a P/E ratio of -0.02 and a beta of 0.64. The business has a fifty day simple moving average of $1.75 and a 200 day simple moving average of $4.23.

Windtree Therapeutics (NASDAQ:WINT) last announced its earnings results on Monday, August 19th. The company reported ($20.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.11) by ($12.80). As a group, sell-side analysts predict that Windtree Therapeutics will post -2.38 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.